drugset
drugset / Trial / NCT04227275

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04227275 ↗

Phase 1 Terminated 16 enrolled Tceleron Therapeutics, Inc.
NaSequentialOpen-labelTreatment

Summary

Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGFβRDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.

Timeline

Start
2019-11-22
Primary completion
2022-11-07
Completion
2022-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CART-PSMA-TGFβRDN Cell therapy — Intravenous
Background Anakinra Protein / enzyme biologic — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

castration-resistant prostate carcinoma